F. Soroko

发表

BW234U,(cis‐9‐[3–(3,5‐dimethyl‐1‐piperazinyl)propyl]carbazole dihydrochloride): a novel antipsychotic agent

B. Cooper, R. Ferris, G. Mckenzie, 1982, The Journal of pharmacy and pharmacology.

7‐(2‐fluorobenzyl)‐4‐(substituted)‐7‐H‐imidazo[4,5‐d −1,2,3‐triazines and −7H‐pyrazolo[3,4‐d]‐1,2,3‐triazines. Synthesis and anticonvulsant activity

B. Cooper, F. Soroko, J. Kelley, 1995 .

Animal models used in prediction of antidepressant effects in man.

B. Cooper, J. L. Howard, F. Soroko, 1983, The Journal of clinical psychiatry.

Potential anticonvulsants. 1. 5-Benzylhydantoins.

F. Soroko, N. B. Mehta, C. A. Diuguid, 1981, Journal of medicinal chemistry.

A role for GABA in the control of ingestive behavior in rats: Effects of ethanolamine-O-sulfate and muscimol

B. Cooper, J. L. Howard, H. White, 1980, Brain Research Bulletin.

Anorexic effects of ethanolamine-O-sulfate and muscimol in the rat: evidence that GABA inhibits ingestive behavior.

B. Cooper, J. L. Howard, H. White, 1980, Life sciences.

Neurochemical and neuropharmacological investigations into the mechanisms of action of bupropion . HCl--a new atypical antidepressant agent.

B. Cooper, R. Ferris, F. Soroko, 1982, Advances in biochemical psychopharmacology.

Synthesis and anticonvulsant activity of 1-benzyl-4-alkylamino-1H-imidazo[4,5-c]pyridines

F. Soroko, J. Kelley, J. A. Linn, 1988 .

Cinromide (3‐bromo‐N‐ethylcinnanamide), a novel anticonvulsant agent

F. Soroko, R. Maxwell, E. Grivsky, 1981, The Journal of pharmacy and pharmacology.

Synthesis and evaluation of the anticonvulsant activity of a series of 2-amino-1-phenyl-1-propanols derived from the metabolites of the antidepressant bupropion

F. Soroko, D. Musso, N. B. Mehta, 1997 .

Synthesis and anticonvulsant activity of a series of benzamides

F. Soroko, G. Boswell, N. B. Mehta, 1996 .

Synthesis and anticonvulsant activity of 3H-imidazo[4,5-c]-pyridazine, 1H-imidazo[4,5-d]pyridazine and 1H-benzimidazole analogues of 9-(2-fluorobenzyl)-6-methylamino-9H-purine

B. Cooper, F. Soroko, J. Kelley, 1995 .

Inhibition of the anticonvulsant activity of l‐dopa by FLA‐63, a dopamine‐β‐hydroxylase inhibitor

G. Mckenzie, F. Soroko, F. E. Soroko, 1973, The Journal of pharmacy and pharmacology.

The effects of apomorphine, (+)‐amphetamine and l‐dopa on maximal electroshock convulsions—a comparative study in the rat and mouse

G. Mckenzie, F. Soroko, 1972, The Journal of pharmacy and pharmacology.

Pro-convulsant actions of theophylline and caffeine in the hippocampus: implications for the management of temporal lobe epilepsy

F. Soroko, Ching M. Wang, B. Ault, 1987, Brain Research.

A Novel Inhibitor of Gamma‐Aminobutyrate Aminotransferase with Anorectic Activity

B. Cooper, H. White, F. Soroko, 1982, Journal of neurochemistry.

Synthesis and anti‐tetrabenazine activity of c‐3 analogues of dimethyl‐2‐phenylmorpholines

B. Cooper, F. Soroko, J. Kelley, 1996 .

2-(Alkoxyaryl)-2-imidazoline monoamine oxidase inhibitors with antidepressant activity.

G. Mckenzie, M. Harfenist, F. Soroko, 1978, Journal of medicinal chemistry.

1-(Fluorobenzyl)-4-amino-1H-1,2,3-triazolo[4,5-c]pyridines: synthesis and anticonvulsant activity.

B. Cooper, C. Koble, F. Soroko, 1995, Journal of medicinal chemistry.

8-Amino-3-benzyl-1,2,4-triazolo[4,3-a]pyrazines. Synthesis and anticonvulsant activity.

B. Cooper, F. Soroko, D. Bankston, 1995, Journal of medicinal chemistry.

On the role of rate of brain norepinephrine release in the antibenzoquinolizine action of desipramine

F. Sulser, F. Soroko, 1965, Psychopharmacologia.

6-(Alkylamino)-9-benzyl-9H-purines. A new class of anticonvulsant agents.

F. Soroko, J. Kelley, J. A. Linn, 1988, Journal of medicinal chemistry.

Bupropion hydrochloride ((±) α‐t‐butylamino‐3‐chloropropiophenone HCl): a novel antidepressant agent

D. H. Schroeder, R. Ferris, F. Soroko, 1977 .

The pharmacologic basis for therapeutic interest in bupropion.

F. Soroko, R. Maxwell, 1983, The Journal of clinical psychiatry.

Bupropion hydrochloride ((+/-) alpha-t-butylamino-3-chloropropiophenone HCl): a novel antidepressant agent.

D. H. Schroeder, R. Ferris, F. Soroko, 1977, The Journal of pharmacy and pharmacology.

Synthesis, stereochemistry and anti‐tetrabenazine activity of bicyclo analogues of 2‐phenylmorpholines

B. Cooper, F. Soroko, J. Kelley, 1997 .

Synthesis and evaluation of the antidepressant activity of the enantiomers of bupropion.

E. Hollingsworth, R. Ferris, F. Soroko, 1993, Chirality.

Models of Depression Used in the Pharmaceutical Industry

B. Cooper, J. L. Howard, G. T. Pollard, 1989 .

The effect of cyproheptadine on food consumption in the fasted rat.

F. Soroko, M. G. Baxter, A. Miller, 1970, British journal of pharmacology.

A simple method for the continuous recording of food consumption in the rat

A A Miller, F E Soroko, F. Soroko, 1971, Laboratory animals.

Potentiation of the behavioral effects of 5‐hydroxytryptophan by BW 1370U87, a selective monoamine oxidase‐A inhibitor

G. Rigdon, F. Soroko, C. Burchall, 1992 .

(2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol: a novel antidepressant agent and selective inhibitor of norepinephrine uptake.

B. Cooper, F. Soroko, J. Kelley, 1996, Journal of medicinal chemistry.

1‐(Fluorobenzyl)‐4‐amino‐1H‐1,2,3‐triazolo(4,5‐c)pyridines: Synthesis and Anticonvulsant Activity.

B. Cooper, C. Koble, F. Soroko, 1996 .

Enzyme induction and inhibition in studies on the pharmacological actions of acetophenetidin.

A. Conney, F. Soroko, R. Koster, 1966, The Journal of pharmacology and experimental therapeutics.

Pharmacological Properties of 403U76, a New Chemical Class of 5‐Hydroxytryptamine‐ and Noradrenaline‐reuptake Inhibitor

B. Cooper, E. Hollingsworth, G. Rigdon, 1995, The Journal of pharmacy and pharmacology.